Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Is treatment with oral risdiplam effective and well-tolerated for infants with spinal muscular atrophy type 1?

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Sergott RC, Amorelli GM, Baranello G, Barreau E, Beres S, Kane S, et al. FIREFISH, SUNFISH, JEWELFISH Working Groups. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy. Ann Clin Transl Neurol. 2021;8:54–65. Epub 2020 Nov 24

    Article  CAS  Google Scholar 

  2. Szollosi A, Donkin C. Arrested theory development: the misguided distinction between exploratory and confirmatory research. Perspect Psychol Sci. 2021;16:717–24. Epub 2021 Feb 16

    Article  Google Scholar 

  3. Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384:915–23. FIREFISH Working GroupEpub 2021 Feb 24

    Article  CAS  Google Scholar 

  4. Darras BT, Masson R, Mazurkiewicz-Bełdzińska M, Rose K, Xiong H, Zanoteli E, et al. Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med. 2021;385:427–35. FIREFISH Working Group

    Article  CAS  Google Scholar 

  5. Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018;16:29.

    Article  Google Scholar 

  6. Lash TL, Vandenbroucke JP. Should preregistration of epidemiologic study protocols become compulsory? Reflections and a counterproposal. Epidemiology. 2012;23:184–8.

    Article  Google Scholar 

  7. Harvey LA. Trial registration: a pre-requisite for publication and an ethical responsibility. Spinal Cord. 2017;55:329–30.

    Article  CAS  Google Scholar 

  8. Vandenbroucke JP. Preregistration of epidemiologic studies: an ill-founded mix of ideas. Epidemiology. 2010;21:619–20.

    Article  Google Scholar 

Download references

Acknowledgements

The Journal Club is a collaboration between the American Academy of Pediatrics – Section on Neonatal Perinatal Medicine and the International Society for Evidence-based Neonatology (EBNEO.org).

Author information

Authors and Affiliations

Authors

Contributions

All authors contributed equally towards initial conception and design, data analysis and interpretation, and manuscript composition and final approval.

Corresponding author

Correspondence to Sheema Gaffar.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gaffar, S., Cayabyab, R. & Ramanathan, R. Is treatment with oral risdiplam effective and well-tolerated for infants with spinal muscular atrophy type 1?. J Perinatol 42, 689–691 (2022). https://doi.org/10.1038/s41372-021-01301-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41372-021-01301-5

Search

Quick links